Gaining Momentum in the Treatment of Eye Disease
Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Using a next generation gene therapy platform, the Ocular BioFactory™, the Company is developing products designed to provide long-term benefit or a functional cure by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye.
Avalanche Biotechnologies Phase 2a and Phase 1 36-month Follow-up Data Conference Call and Webcast
Monday, June 15
5 p.m. ET/2 p.m. PT